Differential Response to Anti-VEGF Regimens in AMD With Early Persistent Retinal Fluid
Reticular Pseudodrusen Not Predictive for Intravitreal Ranibizumab Response in nAMD
Ranibizumab vs. Bevacizumab for nAMD Degeneration With Incomplete Posterior Vitreous Detachment
Outer Retinal Tubulations in Eyes Switched from Intravitreal Ranibizumab to Aflibercept for Exudative AMD Treatment
Recalcitrant Cystoid Macular Edema After PPV
RVO Treated With Low-frequency Intravitreal Ranibizumab
Reduction of Intravitreal Bevacizumab Administrations With Sub-Tenon’s Injection of Triamcinolone Acetonide in Diffuse DME
Eleven Biotherapeutics IND for EBI-031 Now in Effect
Eleven Biotherapeutics announced that the company's Investigational New Drug application for EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 and inhibits all known forms of IL-6 cytokine signaling, for treatment of ocular diseases, is effective. As a result, Eleven is entitled to receive a $22.5 million payment from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) pursuant to the terms of its license agreement with Roche. On June 13, 2016, Eleven announced that it had entered into an exclusive license agreement with Roche for the further development and commercialization of EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. Abbie Celniker, PhD, president and CEO of Eleven Biotherapeutics, said the company looks forward to Roche advancing EBI-031 into the clinical realm to explore its potential use for ocular diseases, such as diabetic macular edema. Read more.
Source: Eleven Biotherapeutics, July 2016
AiVita Awarded CIRM Grant for Development of 3D-Transplantable 'Retinas'
AiVita Biomedical announced that the California Institute for Regenerative Medicine approved the company to collaborate on an early translational research awards grant for development of stem cell-derived 3D-transplantable retinas to treat vision loss. The project is being conducted in collaboration with Assistant Professor Magdalene Seiler, PhD, at the Sue & Bill Gross Stem Cell Research Center at the University of California-Irvine. AiVita's role is to manufacture the 3D-retinal organoids and render the process clinically and commercially compliant using its GMP manufacturing, quality and regulatory systems. UCI's role is to test the product for safety and efficacy in relevant models of retinal degeneration. Read more.
Source: AiVita Biomedical, July 2016
RetroSense Named to MIT Technology Review’s 50 Smartest Companies
RetroSense Therapeutics announced that MIT Technology Review selected RetroSense as one of the 50 Smartest Companies in 2016. Editors at the publication conduct an annual search for the smartest companies with an innovative technology and a practical, yet ambitious, business model. RetroSense is developing a novel gene therapy application of optogenetics to treat retinitis pigmentosa. The company’s Investigational New Drug application for RST-001 received clearance from the U.S. Food and Drug Administration in 2015, and the clinical trial was initiated in early 2016. Read more.
Source: RetroSense Therapeutics, June 2016
Topcon Selected for IBM Global Medical Imaging Collaborative
IBM, which is forming the Watson Health medical imaging collaborative, named Topcon Corp., to be among the collaborative’s 16 partners. The group includes academic medical centers, health systems, ambulatory radiology providers and imaging technology companies. As part of this global effort, members will engage IBM's "augmented intelligence" platform, known as Watson, to extract insight from structured and unstructured data sources including medical imaging data, electronic health records, radiology and pathology reports, laboratory results, doctors' progress notes, medical journals, clinical care guidelines and published outcomes studies. Watson, a cognitive computing system, understands natural language, and can reason and learn over time. Topcon will leverage its family of imaging devices to facilitate and optimize the Watson training process, and accelerate development of products and services that improve the diagnosis and treatment of eye diseases. Read more.
Source: Topcon, June 2016
Bausch + Lomb & Nicox Publish Phase III Study Results
Bausch + Lomb and Nicox announced that the results of a Phase III study for latanoprostene bunod (LBN) ophthalmic solution 0.024% were published in the American Journal of Ophthalmology. The results of the LUNAR study demonstrated that LBN 0.024% administered once daily in the evening was not only non-inferior to timolol maleate 0.5% dosed twice daily in subjects with OAG or OHT over three months of treatment, but also provided significantly greater IOP reduction (p≤0.025) at all but the earliest time point evaluated. Read more.
Source: Bausch & Lomb, July 2016
European Research Offers Potentially Improved Vision for Healthy Eyes
Irish-based research published in Investigative Ophthalmology & Visual Science holds the prospect of sharper vision for individuals who already have good eyesight. While most research in this area has focused on corrective action for those who’ve already suffered vision loss as a result of eye disease, the new study concentrated on those with healthy eyesight, and still found marked improvements in vision among those receiving specific dietary supplements over a year. The CREST (Central Retinal Enrichment Supplementation Trials) study was conducted by the Macular Pigment Research Group at Nutrition Research Centre Ireland, part of the School of Health Sciences at Waterford Institute of Technology. Read more.
Source: Waterford Institute of Technology, June 2016
Eyenuk Announces CE Mark and Commercial Launch of EyeArt 2.0
Eyenuk announced receipt of the CE Mark and launch of the second generation of its fully automated diabetic retinopathy screening software. The company plans to roll out EyeArt 2.0 to select eye-care centers in Europe over the next few months. The commercial launch is supported by a new study of the technology demonstrating 98.3-percent sensitivity in identifying potentially treatable patients with severe nonproliferative or proliferative DR, and/or the presence of surrogate markers for clinically significant macular edema. Read more.
Source: Eyenuk, June 2016
Apple & Donate Life America Enable Eye Organ Donor Registration on iPhone
Apple and Donate Life America announced that iPhone users will be able to sign up to be an organ, eye and tissue donor from the Apple Health app with the release of iOS 10. Through a simple sign-up process, iPhone users can learn more and take action. All registrations submitted from iPhone are sent directly to the National Donate Life Registry managed by Donate Life America. Read more.
Source: Apple, July 2016
New Global AMD Therapeutics Report Released
Research and Markets announced the addition of the “Age Related Macular Degeneration - Pipeline Review, H1 2016” report to its offerings. The report provides comprehensive information on the therapeutic development for AMD, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action, route of administration and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for AMD and special features on late-stage and discontinued projects. Read more.
Source: Research and Markets, May 2016
Retina Implant AG Announces Change in Leadership
Following 12 years of successful development at Retina Implant AG, Dr. Walter-G. Wrobel, CEO of the company, announced his resignation by mutual consent, to take effect September 30, 2016. Dr. Wrobel's departure, along with recent CE-approval of the new Retina Implant Alpha AMS, indicates a new era for the company that will be heavily influenced by navigating the challenges of distribution. Reinhard Rubow, who has been on the board for 13 years, will step up to lead Retina Implant AG as sole executive director, starting October 1, 2016. Read more.
Source: Retina Implant AG, July 2016
Review of Ophthalmology's® Retina Online is published by the Review Group, a Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.
To subscribe to other JMI newsletters or to manage your subscription, click here.
To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.
To ensure delivery, please be sure to add firstname.lastname@example.org to your address book or safe senders list.
Click here if you do not want to receive future emails from Review of Ophthalmology's Retina Online.